Core Viewpoint - The eleventh batch of national organized drug procurement has been initiated, focusing on 55 types of drugs, with an emphasis on ensuring quality, reasonable pricing, and meeting diverse patient needs while promoting healthy development in the pharmaceutical industry [1][2]. Group 1: Procurement Process - The procurement process will enter the reporting phase for medical institutions, adhering to principles of "stabilizing clinical use, ensuring quality, preventing collusion, and avoiding excessive competition" [1]. - The selection of drugs for this batch will exclude newly negotiated drugs that are still under agreement, aiming to protect industry innovation [1][2]. - A total of 122 drugs met the initial selection criteria as of March 31, 2023, with 55 drugs ultimately selected for procurement after further screening [2]. Group 2: Quality Assurance - Stricter quality requirements have been established, mandating that participating companies must have at least two years of production experience for similar formulations, and their production lines must not have violated quality management standards in the past two years [2][3]. - The procurement office will support real-world studies on the clinical efficacy of selected drugs to enhance patient confidence in medication [2]. Group 3: Pricing and Competition - The procurement rules have been optimized to limit excessively low bids, requiring the lowest bidders to justify their pricing and ensure it does not fall below cost [3]. - The procurement will allow medical institutions to report specific brand quantities, aligning their needs with the selected results, thus enhancing the diversity of medication options available [3][4]. Group 4: Procurement Volume - The total reported quantity must not be less than 80% of actual usage, with allowances for adjustments based on clinical demand fluctuations [4]. - The procurement volume will be set between 60% to 80% based on market competition and the number of selected companies, allowing for greater flexibility in brand selection [4]. Group 5: Industry Impact - The ongoing optimization of procurement rules is expected to shift the industry focus from "low-price competition" to "quality competition, cost control, and reasonable profits," thereby enhancing the overall quality and accessibility of medications for the public [4].